Health Care

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study

Health Care Recent News

3 Healthcare Mutual Funds to Ensure a Robust Portfolio
Investors often rely on the healthcare sector to safeguard their investments. This is because healthcare services do not see their demand varying too much with respect to market conditions and thus offer sufficient protection to the capital invested. Many pharmaceutical companies also offer regular dividends.
Why Is HCA Healthcare Stock Trading Lower On Friday?
HCA Healthcare's first-quarter results, surpassing revenue and EPS expectations. CEO Sam Hazen emphasizes sustained momentum and volume growth.
Avantor's Conservative Guidance Is Realistic Post Q1 Earnings Performance: Analyst
Avantor reports Q1 net sales of $1.68 billion, down 5.6% Y/Y. Adjusted EBITDA stands at $283M, with EPS of $0.22, beating consensus.
Centene's First-Quarter Surge: Sales Soar To $40.41B, Exceeding Expectations: What's Next For The Healthcare Company?
Centene outperforms expectations with $40.41 billion in Q1 sales, driven by robust growth in premium revenues and steady membership. Raises full-year guidance amid strong momentum.
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.
West Pharmaceutical Q1 Earnings Beat, HVP Sales Weak
West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to hit €13 billion in 2024 sales. Blockbuster ambitions for Beyfortus.
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
AstraZeneca reports Q1 sales of $12.68 billion, up 17% Y/Y. Despite missing adjusted EPADS, oncology sees a 26% surge, driven by Tagrisso and Imfinzi. Cardiovascular sales up 20%. R&D up 18%. Fiscal 2024 outlook: low double-digit revenue and EPS growth.
What's Going On With Palantir Technologies Today?
Palantir Technologies (PLTR) shares dip premarket despite multi-year partnership with Parexel to enhance clinical trials efficiency using AI platforms.
EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes
Unlock the potential of adaptive immunity with ImmuneSelect by Virax Biolabs. Investigate T-Cell driven immunity for post-viral syndromes like Long COVID. Explore peptide pools and recombinant antibodies for immune profiling.
US Warns Of E. Coli Risk With Eating Ground Beef: How To Keep Yourself Amid USDA Warning
The US FSIS has issued an E. coli health alert, but what E. coli is and how can you stay protected? Here's everything you need to know.
McKinsey Faces Criminal Probe By DOJ For Opioid Consulting: Report
The U.S. Department of Justice is conducting a criminal investigation into the consulting firm McKinsey & Company for its role in advising major opioid manufacturers on increasing sales. The investigation also focuses on potential obstruction of justice related to McKinsey's consulting records for opioid producers.
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers